-
New drug
Good Morning, someone has news about the new drug named Nerandomilast, by Boehringer Ingelhiem?
Best . Massimo
-
7 Replies
-
globenewswire.com
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline...
-
Thanks for sharing the link to more information Alex-Marion! I’m curious to see what happens with the development of this drug and from patients who speak with their physicians about it.
Char.
-
-
Apparently, it will be a new drug in the market with better results, in 2025/6
-
My husband used to work in clinical research for this company, which is privately owned by a German family. He worked in cardiac, not pulmonary, drugs. This drug sounds promising. It should be noted it is for IPF patients, not those whose PF has an identifiable cause, such as my autoimmune disease. Mine is Sjogren’s Syndrome, but other autoimmune diseases and other identifiable causes for PF may lead doctors to try different treatments. Of course, doctors can and do prescribe for “off label” indications if they feel a patient would benefit. I just want to point out, this drug is–for now, at least–only for IPF.
-
I have non specific interstitial pneumonia. Do you know if this drug is appropriate for NSIP?
-
Hi Charlene
I think this will work, otherwise wouldn’t apply to fda .
I did ask s Dr, in Toronto general back in May this year, and they dodge the question with a maybe answer.
I also asked for the trial of Bristol Mayer drug, that fir what I read works better and minimum side effect. This trial still going till end 2025.
Because in 1 year all the patented drugs loose their monopoly, I imagine, they will supply the market with a better one.
Bi 1015550 realy work well in the 12 weeks phase 2, improved fvc, compared yo placebo.
-
Somthing more that looks possitive.
https://6abc.com/temple-lung-center-idiopathic-pulmonary-fibrosis-scar-tissue-breathe/13577878/
6abc.com
Fibroneer could aid in treating pulmonary fibrosis, stop lung scarring
Pulmonary fibrosis turns the lungs to scar tissue, making it harder and harder to breathe. Help may be on the way as a drug being tested locally aims at giving sufferers their breath back.
Log in to reply.